539 related articles for article (PubMed ID: 19926918)
1. Pitavastatin, an HMG-CoA reductase inhibitor, ameliorates endothelial function in chronic smokers.
Yoshida O; Kondo T; Kureishi-Bando Y; Sugiura T; Maeda K; Okumura K; Murohara T
Circ J; 2010 Jan; 74(1):195-202. PubMed ID: 19926918
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein.
Beckman JA; Liao JK; Hurley S; Garrett LA; Chui D; Mitra D; Creager MA
Circ Res; 2004 Jul; 95(2):217-23. PubMed ID: 15178637
[TBL] [Abstract][Full Text] [Related]
3. The effect of pitavastatin calcium on endothelial dysfunction induced by hypercholesterolemia.
Yan HM; Zhao J; Ma DZ; Wang H; Wang J; Wang ZH; Li L; Zhang Y; Zhang W; Zhong M
Expert Opin Pharmacother; 2011 Jul; 12(10):1463-71. PubMed ID: 21651447
[TBL] [Abstract][Full Text] [Related]
4. Effects of vitamin E on chronic and acute endothelial dysfunction in smokers.
Neunteufl T; Priglinger U; Heher S; Zehetgruber M; Söregi G; Lehr S; Huber K; Maurer G; Weidinger F; Kostner K
J Am Coll Cardiol; 2000 Feb; 35(2):277-83. PubMed ID: 10676670
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin normalizes endothelial function in healthy smokers.
Agewall S; Hernberg A
Clin Sci (Lond); 2006 Jul; 111(1):87-91. PubMed ID: 16608440
[TBL] [Abstract][Full Text] [Related]
6. Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor.
Takayama T; Wada A; Tsutamoto T; Ohnishi M; Fujii M; Isono T; Horie M
Circ J; 2004 Nov; 68(11):1067-75. PubMed ID: 15502390
[TBL] [Abstract][Full Text] [Related]
7. Endothelial function in subjects with isolated low HDL cholesterol: role of nitric oxide and circulating progenitor cells.
Higashi Y; Matsuoka H; Umei H; Sugano R; Fujii Y; Soga J; Kihara Y; Chayama K; Imaizumi T
Am J Physiol Endocrinol Metab; 2010 Feb; 298(2):E202-9. PubMed ID: 19903864
[TBL] [Abstract][Full Text] [Related]
8. Improvement of endothelial function by pitavastatin: a meta-analysis.
Katsiki N; Reiner Ž; Tedeschi Reiner E; Al-Rasadi K; Pirro M; Mikhailidis DP; Sahebkar A
Expert Opin Pharmacother; 2018 Feb; 19(3):279-286. PubMed ID: 29334477
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet.
Yoshida M; Nakamura K; Miyoshi T; Yoshida M; Kondo M; Akazawa K; Kimura T; Ohtsuka H; Ohno Y; Miura D; Ito H
Cardiovasc Diabetol; 2020 Sep; 19(1):149. PubMed ID: 32979918
[TBL] [Abstract][Full Text] [Related]
10. MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/2-dependent pathway.
Hiraoka M; Nitta N; Nagai M; Shimokado K; Yoshida M
Life Sci; 2004 Jul; 75(11):1333-41. PubMed ID: 15234191
[TBL] [Abstract][Full Text] [Related]
11. Biphasic effect of HMG-CoA reductase inhibitor, pitavastatin, on vascular endothelial cells and angiogenesis.
Katsumoto M; Shingu T; Kuwashima R; Nakata A; Nomura S; Chayama K
Circ J; 2005 Dec; 69(12):1547-55. PubMed ID: 16308507
[TBL] [Abstract][Full Text] [Related]
12. Pitavastatin calcium improves endothelial function and delays the progress of atherosclerosis in patients with hypercholesterolemia.
Zhao J; Yan HM; Li Y; Wang J; Han L; Wang ZH; Tang MX; Zhang W; Zhang Y; Zhong M
J Zhejiang Univ Sci B; 2015 May; 16(5):380-7. PubMed ID: 25990055
[TBL] [Abstract][Full Text] [Related]
13. Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastatin, in a rat model of hypertension and hypercholesterolemia.
Kumai T; Oonuma S; Matsumoto N; Takeba Y; Taniguchi R; Kamio K; Miyazu O; Koitabashi Y; Sekine S; Tadokoro M; Kobayashi S
Life Sci; 2004 Mar; 74(17):2129-42. PubMed ID: 14969717
[TBL] [Abstract][Full Text] [Related]
14. Effect of green tea consumption on endothelial function and circulating endothelial progenitor cells in chronic smokers.
Kim W; Jeong MH; Cho SH; Yun JH; Chae HJ; Ahn YK; Lee MC; Cheng X; Kondo T; Murohara T; Kang JC
Circ J; 2006 Aug; 70(8):1052-7. PubMed ID: 16864941
[TBL] [Abstract][Full Text] [Related]
15. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species.
Wassmann S; Laufs U; Bäumer AT; Müller K; Ahlbory K; Linz W; Itter G; Rösen R; Böhm M; Nickenig G
Hypertension; 2001 Jun; 37(6):1450-7. PubMed ID: 11408394
[TBL] [Abstract][Full Text] [Related]
16. Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes--a multicenter, randomised, double-blind, three-arm placebo-controlled clinical trial.
Balletshofer BM; Goebbel S; Rittig K; Enderle M; Schmölzer I; Wascher TC; Ferenc Pap A; Westermeier T; Petzinna D; Matthaei S; Häring HU
Exp Clin Endocrinol Diabetes; 2005 Jun; 113(6):324-30. PubMed ID: 15977099
[TBL] [Abstract][Full Text] [Related]
17. Pitavastatin: an overview.
Saito Y
Atheroscler Suppl; 2011 Nov; 12(3):271-6. PubMed ID: 22152281
[TBL] [Abstract][Full Text] [Related]
18. Nifedipine improves endothelial function: role of endothelial progenitor cells.
Sugiura T; Kondo T; Kureishi-Bando Y; Numaguchi Y; Yoshida O; Dohi Y; Kimura G; Ueda R; Rabelink TJ; Murohara T
Hypertension; 2008 Sep; 52(3):491-8. PubMed ID: 18645050
[TBL] [Abstract][Full Text] [Related]
19. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Rosenson RS
Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
[TBL] [Abstract][Full Text] [Related]
20. Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency.
Yagi S; Aihara K; Ikeda Y; Sumitomo Y; Yoshida S; Ise T; Iwase T; Ishikawa K; Azuma H; Akaike M; Matsumoto T
Circ Res; 2008 Jan; 102(1):68-76. PubMed ID: 17967781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
